- Tristel
- 29 July 2025 14:53:05
Source: Sharecast
The AIM-traded company confirmed that its results were in line with market expectations, marking another year of significant growth.
For the year, Tristel recorded an 11% increase in revenue to £46.5m, up from £41.9m inFY 2024.
The growth aligned with the company’s performance target of a 10% to 15% annual revenue increase over the last three years.
It also saw a 15% rise in second-half revenue on a constant currency basis, indicating strong demand for its infection prevention products.
Adjusted profit before tax for the year grew 23%, reaching no less than £10.1m, compared to £8.2m in the prior year, in line with expectations.
Tristel said it remains debt-free and cash-generative, with cash balances at £12.8m as of 30 June, an increase from £11.8m in June 2024.
“As I approach the one year mark as CEO, we are pleased to have delivered another year of strong growth, fully aligned with our strategic targets,” said chief executive Matt Sassone.
“Demand for our infection prevention technologies remains robust across all regions, including our newly established North American markets.”
He said that achieving 11% revenue growth and a 23% uplift in adjusted profit before tax reflected the resilience of Tristel’s business model, as well as the commitment of its global team.
“We have further strengthened our Board with the addition of our new CFO, Anna Wasyl, who will join us in September, and we look forward to capitalising on her expertise as we enter the next phase of growth.
“We remain debt-free, cash-generative, and confident in our ability to sustain this momentum as we look to the year ahead.”
The company said it was optimistic about continuing its growth trajectory, bolstered by strong demand for its products and a solid financial foundation heading into the next financial year.
At 1419 BST, shares in Tristel were up 2.08% at 382.8p.
Reporting by Josh White for Sharecast.com.